What’s Happening in the Alzheimer’s Research Field?

Diversity Matters: AD Looks Different Among Hispanic Patients

A new autopsy study out of the University of California San Diego School of Medicine found that Hispanics with mild-to-moderate AD in the study were significantly less impaired than similar non-Hispanic patients. This suggests there are multiple factors that influence the profile of cognitive deficits in AD, which going forward will help guide how Hispanic populations are diagnosed with and live with AD.  The research also helps to highlight the critical need for increased minority participation in research.

Minority Participation in Research: A lack of will, or an absence of welcome?

This article addresses how low minority participation in research, in New York City and around the country, impacts the development of new medicines. The author provides a look at the value of research participation, while acknowledging the historical and structural barriers that limit participation from Blacks, Latinos and Asians. Critically, the article challenges that the problem is in the lack of welcoming from research institutions to these groups, rather than their lack of will to participate.

Looking for AD research for you or someone you know? Sign up with the Alzheimer’s Association’s TrialMatch.

Could Alzheimer’s be born in our mouth?

New evidence suggests a bacterium commonly associated with gum disease could be driving AD pathology. While more research is needed, a team of international scientists, led by Cortexyne Inc. a clinical stage pharmaceutical company, found that in animal models an oral infection of Porphyromonas gingivalis (Pg) led to brain colonization and an increase of amyloid beta, a component of amyloid plaque. The team also found Pg’s toxic enzymes (called gingipains) in the neurons of human AD patients, which can cause inflammation and amyloid beta production. This has paved the way for pharmaceutical therapies targeting gingipains. 

Stay tuned to our LinkedIn page for more updates on Cortexyme’s next phase of research and other studies like it.

What People Say About Working With Us

“Bringing research to my community allowed me to open doors with my families – it gave me a tool to reach out to them.” 

Jamie Glavich, Founder and Owner of Almost Home Senior Services, Jacksonville, FL

What’s Coming Down the Alzheimer’s Research Pipeline?

Despite recent trial failures, optimism reigns

CEO and CMO of ProMIS Neurosciences express their optimism for a disease modifying treatment, in a recent interview. They predict that lessons learned from recent trial failures, including the most recent Roche trial of crenezumab, will produce one or two new therapies by 2025, along with a host of new AD biomarkers

How Can I Get Involved With Recruitment Partners?

Ready to take the first step?

Contact Erin Beck, Director, Site Recruitment and Management to complete the Care Community Questionnaire. 


Leave a Reply

Your email address will not be published. Required fields are marked *